$A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents$

A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents

Purpose: To evaluate the treatment outcomes of aflibercept in patients with exudative age-related macular degeneration (AMD) resistant to other anti-vascular endothelial growth factor (VEGF) medications (bevacizumab, ranibizumab, and combination with or without dexamethasone and laser photocoagulati...

Full description

Saved in:

Bibliographic Details
Main Author:	Kiran Turaka
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2014-04-01
Series:	Delhi Journal of Ophthalmology
Subjects:	aflibercept bevacizumab macular degeneration ranibizumab vascular endothelial growth factor
Online Access:	https://journals.lww.com/10.7869/djo.51
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice
by: R. R. Fayzrakhmanov
Published: (2019-06-01)

Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study
by: Mekala Shellvarajah, et al.
Published: (2025-04-01)

Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration
by: I. E. Ioshin, et al.
Published: (2019-08-01)

12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept
by: Wajiha J Kheir, et al.
Published: (2025-01-01)

Structural and Functional Criteria of Neuroprotection Effectiveness after Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration
by: N. S. Zhajvoronok, et al.
Published: (2019-12-01)

Pharmacological Analysis of Resistance to Anti-VEGF Therapy
by: M. V. Budzinskaya, et al.
Published: (2019-01-01)

Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration
by: S. V. Nedogoda, et al.
Published: (2020-03-01)

Anti-VEGF agents in the treatment of diabetic macular edema
by: Vladimir Iosifovich Konenkov, et al.
Published: (2013-12-01)

Polypoidal Choroidal Vasculopathy Treatment: Photodynamic Therapy, Anti-VEGF Monotherapy or Combination. Review of Clinical Studies
by: E. K. Pedanova, et al.
Published: (2019-06-01)

Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration
by: Masaaki Saito, et al.
Published: (2025-08-01)

Efficacy of Aflibercept (8 mg) for Diabetic Macular Edema in Vitrectomized Eyes Refractory to the Other Anti-VEGF Drug Therapies: A Report of Three Cases
by: Kashiwagi I, et al.
Published: (2025-04-01)

Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration
by: Bhagya Weerasinghe, et al.
Published: (2021-01-01)

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF
by: H. Mhmud, et al.
Published: (2025-06-01)

Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study
by: Chakraborty D, et al.
Published: (2024-11-01)

Incidence and Clinical Practice of Myopic Macular Neovascularization: A Nationwide Population-Based Cohort Study
by: Masahiro Akada, MD, et al.
Published: (2025-11-01)

Comparative efficacy and safety of Faricimab with other intravitreal anti-vascular endothelial growth factor in the treatment of Neovascular age related macular degeneration- A Systematic review and meta-analysis
by: Renuga Devi Kaliaperumal, et al.
Published: (2025-05-01)

Long-term results of anti-VEGF therapy in macular edema caused by central retinal vein occlusion
by: A. B. Galimova, et al.
Published: (2023-12-01)

Peptide‐Bound Aflibercept Eye Drops for Treatment of Neovascular Age‐Related Macular Degeneration in Nonhuman Primates
by: Xingyan Fan, et al.
Published: (2025-03-01)

Efficacy and safety of intravitreal anti-VEGF for myopic choroidal neovascularization
by: Jing-Yao Liu, et al.
Published: (2025-09-01)

Effectiveness of aflibercept in treating bevacizumab resistant macular edema
by: Hussain Khudair Yassin
Published: (2024-12-01)

Intravitreal bevacizumab for neovascular age-related macular degeneration
by: Junn R. Pajarillo, MD, et al.
Published: (2009-12-01)

Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
by: Aljuhani HS, et al.
Published: (2025-06-01)

Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom
by: Muiz Musadiq, et al.
Published: (2025-06-01)

Tailored Anti-VEGF Therapy with New Generation Optimizations (TANGO) Treatment Regimen for Neovascular Age-Related Macular Degeneration: Rationale, Design, and Simulation Study
by: Subhi Y, et al.
Published: (2025-04-01)

Long-Term Outcomes of Nonadherence to Anti-VEGF Therapy in Advanced Neovascular Age-Related Macular Degeneration
by: A. N. Kulikov, et al.
Published: (2022-10-01)

Endophthalmitis following intravitreal injections at a tertiary center: real-life data on incidence, risk factors, management strategies, and visual outcomes
by: Sebile Comcali, et al.
Published: (2025-05-01)

Assessment of effect of intravitreal ranibizumab injection on the ocular blood flow in patients with neovascular age-related macular degeneration
by: V. V. Neroev, et al.
Published: (2014-07-01)

Early optical coherence tomography biomarkers for tailored frequency of intravitreal aflibercept in neovascular age-related macular degeneration
by: Gyeongsoo Lim, et al.
Published: (2025-03-01)

Efficacy of aflibercept in patients with neovascular age-related macular degeneration when combined with cataract surgery
by: A. A. Kuznetsov, et al.
Published: (2018-10-01)

A pilot study : retinal sensitivity change in neovascular age-related macular degeneration patients with better baseline visual acuity
by: Jae Hyup Lee, et al.
Published: (2024-11-01)

Predicting response to anti-VEGF therapy in neovascular age-related macular degeneration using random forest and SHAP algorithms
by: Peng Zhang, et al.
Published: (2025-06-01)

Anti-VEGF combined with fufang xueshuangtong versus anti-VEGF monotherapy for wet age-related macular degeneration: A meta-analysis
by: Tingke Xie, et al.
Published: (2025-06-01)

Evidence for Whom? A Systematic Review of Eligibility Criteria in RCTs of Anti-VEGF for Neovascular Age-Related Macular Degeneration
by: Andreas Arnold-Vangsted, et al.
Published: (2025-07-01)

Short-term Outcomes of Anti-VEGF therapy in Neovascular Age-related Macular Degeneration with Initially Low Visual Acuity
by: A. N. Kulikov, et al.
Published: (2025-03-01)

The Effects of VEGF Signal Pathway on Etiopathogenesis and AntiVEGF Treatments in Childhood Cancers
by: Ali Kazdal, et al.
Published: (2023-09-01)

Factors Affecting Compliance to Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Age-Related Macular Degeneration
by: Onur Polat, et al.
Published: (2017-08-01)

The results of diagnostic and treatment of patients with diabetic retinopathy and age-related macular degeneration at a diabetes type 2.
by: I. V. Vorobyova, et al.
Published: (2014-10-01)

Role of Anti VEGF Agent in Management of Primary Pterygium
by: Abhinav Singh, et al.
Published: (2018-10-01)

Comparison of three loading doses of bevacizumab and ranibizumab for macular edema due to branch retinal vein occlusion
by: Sibel Coşkun Akdemir, et al.
Published: (2025-05-01)

Continuous versus Intermittent Use of Tear Substitutes in Patients Treated with Anti-VEGF for Neovascular Age-Related Macular Degeneration: The TREDIA Study
by: Héloïse Torres-Villaros, et al.
Published: (2025-07-01)